 Oragenics Inc. NYSE:OGEN shares skyrocketed higher Tuesday after the company entered into a licensing agreement with the National Research Council of Canada to pursue the rapid development of next-generation SARS-CoV-2 vaccines. This platform should allow productions of cell lines within six to eight weeks compared to six to nine months for traditional production. 